Get updates in your inbox.
The Moderna COVID-19 vaccine was and did not worsen clinical symptoms in other people with myasthenia gravis (MG), a Spanish study reported.
Patients developed a physically powerful immune reaction after receiving the two recommended doses, even though they were under immunosuppressive treatments. In addition, no participants developed COVID-19 in the study.
The study, “Immune Response and Safety of the SARS-CoV-2 mRNA-1273 Vaccine in Patients with Myasthenia Gravis,” published in the journal Neurology: Neuroimmunology
In MG, the immune formula mistakenly attacks proteins involved in nerve-muscle communication, which basically causes muscle weakness. The muscles involved in breathing, as well as those of the eyes, face, arms, and legs, can be affected.
Infections, surgery, and certain medications are known causes of exacerbations of the disease or periods when symptoms are more severe. Since vaccines elicit an immune reaction to induce coverage in the face of an express threat, some members of the medical network engage in advocacy. and vaccine efficacy evolved against SARS-CoV-2, the virus that causes COVID-19, in patients on immunosuppressive therapy. Treatments.
Spanish researchers have studied the protection and efficacy of the Moderna COVID-19 vaccine (mRNA-1273), which is based on a new technology. mRNA vaccines provide command cells to produce an innocent piece of the SARS-CoV-2 spike protein. Traditional vaccines consist of inactivated viruses or viral proteins that elicit the body’s immune response.
Their study was conducted from April to November 2021 in a vaccination campaign, with patients to receive the two recommended doses, administered 28 days apart.
Blood samples were taken before the first dose given and 3 months after the current dose of the vaccine.
Clinical decisions were made at the beginning of the study and one week after the first and last dose, using the MG Activities of Daily Living Score (MG-ADL), a patient-reported survey assessing the severity of MG symptoms Changes in symptoms were thought to be clinically applicable only with an accumulation in the MG-ADL score of 3 or more.
Of the one hundred patients enrolled, 99 received either dose of the vaccine. A total of 83 other people had generalized MG, a more severe and widespread form of the disease, and 17 had ocular MG, a form of disease in which weakness is limited to the muscles that control eye and eyelid movements. The average duration of the group’s disease was almost 12 years.
Although symptoms were to worsen after the first dose and timing, increases in MG-ADL scores were less than two points. Therefore, those amendments were not clinically relevant.
Blood was collected from a total of 98 participants. After vaccination, the majority of patients (88. 8%) developed antibodies opposite to the SARS-CoV-2 spike protein. All those who were not employing the popular therapy of MG, immunosuppressive drugs, developed a humoral immune reaction that is characterized by the production of antibodies. The humoral immune reaction decreased only slightly in immunocompromised patients (86. 7%).
Further research showed that patients who received a combination treatment of prednisone and other immunosuppressants had a nearly six-fold increased risk of developing antibodies against the spike protein.
T cell immune reactions, which are considered vital to delivering a sustained immune reaction to COVID-19, were decided by measuring interferon gamma levels in the blood. Participants were grouped according to whether they had positive effects for interferon. gamma or negative for interferon gamma.
Of the 98 patients, 72 tested positive for interferon gamma (73. 47%) and therefore showed a mobile T reaction after vaccination. to achieve an immune reaction of T-mobiles after vaccination than patients in monotreatment. “
Fourteen patients reported side effects after the first dose of the vaccine and 21 after the current dose. These were mild and included headache, pain at the injection site, fatigue, fever, abdominal pain or vomiting, and diarrhea. No serious side effects were reported.
Patients who won either dose increased SYMPTOMS of COVID-19 over the next six months.
“Our effects imply that the mRNA-1273 vaccine does not cause significant [side effects] or an applicable worsening of the clinical condition of PATIENTS with MG. Although they won immunosuppressive therapy, patients in this study achieved significant humoral and cellular immune responses, and none of those who finished the vaccination regimen developed COVID-19 in an era of peak incidence,” the team wrote.
“Taken together, these effects verify the protection and efficacy of the mRNA-1273 vaccine in MG. “
Myasthenia Gravis News conducted a survey from February 11 to March 28 to better understand the characteristics of the MG network and disease control. The effects of the survey have already been published. Click on the symbol to view the infographic and click here to Read the story.
Get updates in your inbox.
This site is strictly a news and data site about the disease. It does not provide medical recommendations, diagnoses or treatments. This content is not intended to update professional medical recommendations, diagnoses or treatments. provider of care for any questions you may have regarding a medical condition. Never forget the professional medical recommendation or stop it because of something you have read on this website.